AXLA Axcella Health Inc.

6
+0.33  (+6%)
Previous Close 5.67
Open 5.68
Price To Book 1.86
Market Cap 215,032,896
Shares 35,838,816
Volume 437,913
Short Ratio
Av. Daily Volume 248,042
Stock charts supplied by TradingView

NewsSee all news

  1. Axcella Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option

    Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced

  2. Axcella Announces Pricing of Public Offering of Common Stock

    Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced

  3. Axcella Reports First Quarter Financial Results and Provides Business Update

    Reported positive top-line data from AXA1125-003, with clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation observed in subjects with NAFLD receiving AXA1125 Completed

  4. Axcella Announces Positive Top-Line Data from AXA1125-003 Clinical Study Showing Multifactorial Activity in Adult Subjects with NAFLD

    Clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation markers observed with AXA1125 along with favorable tolerability, supporting its potential to be a first-line NASH therapy

  5. Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD on May 6, 2020

    Company to hold conference call at 8:30 a.m. ET Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b/3 trial to be initiated 4Q 2020.
AXA1665
Hepatic encephalopathy
Phase 2b trial planned.
AXA1125
Nonalcoholic steatohepatitis (NASH

Latest News

  1. Axcella Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option

    Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced

  2. Axcella Announces Pricing of Public Offering of Common Stock

    Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced

  3. Axcella Reports First Quarter Financial Results and Provides Business Update

    Reported positive top-line data from AXA1125-003, with clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation observed in subjects with NAFLD receiving AXA1125 Completed

  4. Axcella Announces Positive Top-Line Data from AXA1125-003 Clinical Study Showing Multifactorial Activity in Adult Subjects with NAFLD

    Clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation markers observed with AXA1125 along with favorable tolerability, supporting its potential to be a first-line NASH therapy

  5. Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD on May 6, 2020

    Company to hold conference call at 8:30 a.m. ET Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex

  6. Axcella to Hold Virtual-Only 2020 Annual Meeting of Stockholders

    Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced

  7. Axcella Receives Fourth Patent Covering EMM Compositions

  8. Axcella Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    Announced positive interim findings from ongoing clinical study of AXA1125 and AXA1957; expect to report top-line data in second quarter of 2020 Completed enrollment in ongoing clinical study of AXA1665; expect to

  9. Axcella Announces Oral Presentation at 2020 International Conference on Frailty and Sarcopenia Research

    Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced

  10. Axcella Completes Enrollment of Subjects in AXA1665-002 Study

    60 subjects enrolled in AXA1665-002 Top-line data expected in mid-2020 IND submission for overt hepatic encephalopathy and initiation of potential registrational Phase 2b/3 clinical trial planned for second half of

  11. Axcella to Present at the SVB Leerink 9th Annual Global Healthcare Conference

    Presentation and webcast to take place at 9:00 a.m. ET on February 26 Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach

  12. Axcella to Present at J.P. Morgan Healthcare Conference

    Presentation and webcast to take place at 11:30 a.m. ET on January 16 Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach

  13. Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones

    Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early as eight weeks Interim data support candidates' potential to become

  14. Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

    CAMBRIDGE, Mass., Dec. 16, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently

  15. Flagship Pioneering Unveils Cellarity, the First Company to Discover Medicines Targeting Cell Behavior

    CAMBRIDGE, Mass., Dec. 10, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, unveiled Cellarity, a first-of-its-kind therapeutics company that is discovering and developing medicines

  16. Axcella Presents Data at ASH Annual Meeting

    Preclinical mechanistic data for constituents of AXA4010 demonstrate multifactorial potential of endogenous metabolic modulators (EMMs) on red blood cell, immune and vascular health Axcella Health Inc. (NASDAQ:AXLA), a

  17. Axcella Strengthens Executive Team with Key Addition and Promotion

    Appoints Laurent Chardonnet as Chief Financial Officer Promotes Heidy King-Jones to General Counsel Axcella Health (NASDAQ:AXLA), a biotechnology company pioneering the research and development of novel

  18. Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957

    Completed enrollment in AXA1125 and AXA1957 study in adults with NAFLD Initiated enrollment of AXA1957 study in adolescents with NAFLD Developing AXA1125 and AXA1957 as therapeutic agents for NASH Axcella Health

  19. Axcella Announces Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting

    Axcella Health Inc. (NASDAQ:AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced that the